{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:45:24Z","timestamp":1763142324666,"version":"3.41.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Well-differentiated neuroendocrine neoplasms (NETs) overexpress the somatostatin receptor, which is the target for the peptide receptor radionuclide therapy (PRRT). NETs have a slow growth rate and can metastasize to liver, bone, and lungs. In NETs patients, liver metastasis is an important prognostic marker because liver failure is one of the most common causes of death in this population. In this regard, we aimed to describe the changes in laboratorial parameters in patients submitted to PRRT with <jats:sup>177<\/jats:sup>Lu-DOTATATE, focusing on hepatic parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>One hundred ten patients treated with 1 to 4 cycles of 7.4 GBq (200 mCi) of <jats:sup>177<\/jats:sup>Lu-DOTATATE from January 2011 to December 2021 were analyzed in this retrospective observational single-center study. Patients were submitted to blood tests before and after each cycle of PRRT. Laboratory measurements were collected to assess liver function, cholestasis, kidney, and bone marrow function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the general population (n = 110), ALP (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.013) and GGT (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) showed a statistically significant reduction. Patients with high liver disease volume showed a statistically significant reduction in ALT (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.016), whereas patients with low liver disease volume showed a statistically significant reduction in GGT (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.013). All parameters for bone marrow function showed a statistically significant decrease in all population subsets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE showed a significant improvement in liver function and cholestasis parameters, and a consistent decrease in bone marrow function, even in the presence of advanced liver disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005375","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T14:01:39Z","timestamp":1722520899000},"page":"917-923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Improvement of Laboratory Hepatic Parameters After Treatment With 177Lu-DOTATATE"],"prefix":"10.1097","volume":"49","author":[{"given":"Filipe","family":"dos Santos Soares","sequence":"first","affiliation":[{"name":"Nuclear Medicine Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Ribeiro","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Abdomen Surgery, National Cancer Institute, Rio de Janeiro, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz Arruda Matheos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Christian Martins","family":"Felix","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Alves","family":"Bulzico","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Brunelli","family":"Pujatti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Service"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.32074\/1591-951X-227","article-title":"Introduction to neuroendocrine neoplasms of the digestive system: definition and classification","volume":"113","year":"2021","journal-title":"Pathologica"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","article-title":"New PET radiotracers for the imaging of neuroendocrine neoplasms","volume":"23","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1002\/cam4.2567","article-title":"Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: a population-based study","volume":"8","year":"2019","journal-title":"Cancer Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jso.24563","article-title":"Neuroendocrine liver metastasis: the chance to be cured after liver surgery","volume":"115","year":"2017","journal-title":"J Surg Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"726","DOI":"10.20344\/amp.7306","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumors with 177Lu-DOTA-TATE: experience of the Portuguese Institute of Oncology in Porto","volume":"29","year":"2016","journal-title":"Acta Med Port"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","year":"2020","journal-title":"Histopathology"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-022-03133-5","article-title":"Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients","volume":"78","year":"2022","journal-title":"Endocrine"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.ijrobp.2023.06.2331","article-title":"Experience with 177Lu-Dotatate in patients with metastatic gastroenteropancreatic neuroendocrine tumors at a single urban cancer center","volume":"117","year":"2023","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","year":"2018","journal-title":"Oncotarget"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:00:19Z","timestamp":1750532419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005375"}},"subtitle":["Cohort in an Oncology Reference Center"],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005375","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}